Skip to content

Prospective Evaluation of Asians With CRT for Heart Failure

Prospective Evaluation of Asians With CRT for Heart Failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02814942
Acronym
PEACH
Enrollment
500
Registered
2016-06-28
Start date
2011-01-31
Completion date
2030-12-31
Last updated
2021-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Resynchronisation Therapy, Heart Failure

Brief summary

Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT. Methodology:Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure. The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of \>/= 15% and/or an increase in the LVEF of \>/= 10%.

Detailed description

Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, comorbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure. The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of \>/= 15% and/or an increase in the LVEF of \>/= 10%.

Interventions

DEVICECardiac Resynchronization Therapy

Cardiac resynchronization therapy with or without ICD

Sponsors

National University Heart Centre, Singapore
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Broad QRS (\>120 ms) * EF \< 40% * Symptomatic heart failure * Not on optimal medical therapy

Exclusion criteria

* Pregnant * \< 18 years of age * Infection * Unable to consent

Design outcomes

Primary

MeasureTime frameDescription
Echocardiographic response to CRT6 monthsA subject is considered an echocardiographic responder to CRT if there is: 1. reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of \>/= 15% OR 2. an increase in the LVEF of \>/= 10% during follow-up echocardiography at 6 months

Secondary

MeasureTime frameDescription
Neuroendocrine response to CRT6 monthsA subject is considered to have a neuro-endocrine response to CRT if BNP levels at 6 months post CRT implant has fallen more than 30% from baseline
Clinical response to CRT6 monthsA subject is considered a positive clinical responder to CRT if: 1. NYHA class has improved by at least 1 class OR 2. 6 minutes walking test has increased by at least 10%
Hospitalization For Cardiovascular events8 yearsHospitalisation for acute coronary syndrome, heart failure, arrhythmias, ICD shocks or any unplanned admissions for any cardiac interventions or surgery
Mortality8 yearsMortality

Countries

Singapore

Contacts

Primary ContactPipin Kojodjojo, MD PHD
67795555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026